^
Association details:
| Biomarker: | HRD |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Association of BRCA1/2, homologous recombination deficiency, and PD-L1 with clinical outcomes in patients receiving atezolizumab versus placebo combined with carboplatin, paclitaxel, and bevacizumab for newly diagnosed ovarian cancer: Exploratory analyses
Published date:
03/19/2021
Excerpt:
Neither BRCA1/2m nor HRD was associated with greater clinical benefit from adding atezolizumab to CPB. This is the first randomized double-blind trial in ovarian cancer to demonstrate that genomic instability triggered by BRCA1/2m or HRD does not improve sensitivity to immune checkpoint inhibitors.
